Research map: Investigational interleukin 17A antagonists in the treatment of psoriatic arthritis

Back to the article

Papers in this map

  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials · Richard G B Langley · 2014 · 2005 citations · Cited by this paper
  2. Advancements in longevity pharmacology research – are we finally seeing clinical progression? · 2026 · Related
  3. Psoriatic arthritis: epidemiology, clinical features, course, and outcome · Dafna D. Gladman · 2005 · 1544 citations · Cited by this paper
  4. Placebo-controlled trial of pharmacokinetics, pharmacodynamics and tolerability of KL130008 capsule in patients with rheumatoid arthritis · 2025 · Related
  5. Psoriatic Arthritis · Christopher T. Ritchlin · 2017 · 1422 citations · Cited by this paper
  6. Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a) · 2025 · Related
  7. Pathogenetic insights from the treatment of rheumatoid arthritis · Iain B. McInnes · 2017 · 1379 citations · Cited by this paper
  8. The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates · 2026 · Related
  9. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update · Laure Gossec · 2020 · 961 citations · Cited by this paper
  10. Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates · 2026 · Related
  11. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial · Philip J. Mease · 2005 · 912 citations · Cited by this paper
  12. Assessing the clinical progress of muvalaplin for reducing lipoprotein(a) · 2025 · Related
  13. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial · Iain B. McInnes · 2015 · 865 citations · Cited by this paper
  14. Menin inhibitors for adult acute myeloid leukemia: 2025 update · 2025 · Related
  15. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis · Kenneth B. Gordon · 2016 · 857 citations · Cited by this paper
  16. Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much? · 2026 · Related
  17. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis · Mark Lebwohl · 2015 · 829 citations · Cited by this paper
  18. Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management? · 2026 · Related
  19. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis · Andrew Blauvelt · 2018 · 795 citations · Cited by this paper
  20. Safety, pharmacokinetics, and bioequivalence of vunakizumab injection, a specific dermatitis drug, in healthy Chinese volunteers: an open-label, randomized, two-stage, two-sequence cross-over study · 2025 · Related
  21. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force · Josef S Smolen · 2017 · 688 citations · Cited by this paper
  22. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies · Farzad Alinaghi · 2018 · 671 citations · Cited by this paper
  23. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis · Muhammad Aneeq Haroon · 2014 · 633 citations · Cited by this paper
  24. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021 · Laura C. Coates · 2022 · 626 citations · Cited by this paper
  25. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 · Philip J. Mease · 2016 · 586 citations · Cited by this paper
  26. The pathogenesis of psoriatic arthritis · Douglas James Veale · 2018 · 585 citations · Cited by this paper
  27. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis · Philip J. Mease · 2017 · 575 citations · Cited by this paper
  28. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases · Taku Kuwabara · 2017 · 528 citations · Cited by this paper
  29. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis · Vinod Chandran · 2009 · 523 citations · Cited by this paper
  30. The Epidemiology of Psoriatic Arthritis · Alexis Ogdie · 2015 · 517 citations · Cited by this paper
  31. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors · Dafna D. Gladman · 2017 · 517 citations · Cited by this paper
  32. Enthesitis: from pathophysiology to treatment · Georg Andreas Schett · 2017 · 511 citations · Cited by this paper
  33. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study · Alexis Ogdie · 2014 · 498 citations · Cited by this paper
  34. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis · Jasvinder A. Singh · 2018 · 493 citations · Cited by this paper
  35. Basic biology and role of interleukin‐17 in immunity and inflammation · Camille Zenobia · 2015 · 479 citations · Cited by this paper
  36. The IL-17 family in diseases: from bench to bedside · Longjie Huangfu · 2023 · 459 citations · Cited by this paper
  37. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial · Peter T. Nash · 2017 · 413 citations · Cited by this paper
  38. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition · José U. Scher · 2019 · 400 citations · Cited by this paper
  39. Affibody Molecules in Biotechnological and Medical Applications · Stefan Ståhl · 2017 · 394 citations · Cited by this paper

Source: OpenAlex (CC0)